NL-OMON36459尚未招募不适用
The use of the electronic nose in the diagnosis of patients with rheumatoid arthritis or psoriatic arthritis - e-nose RA and psoriatic arhtritis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •RA patients 18-75 years with:
- •RA according to the ACR criteria
- •DAS28 * 3.2
- •No medication, or methotrexaat / hydroxychloroquine / sulfasalazine / leflunomide and/or prednison stable use * 28 days;Psoriatic arthritis patients 18-75 years with:
- •PsA according to the CASPAR criteria
- •DAS28 * 3.2
- •No medication, or methotrexaat / sulfasalazine / leflunomide/ prednison stable use * 28 days;Controls
- •Non-smoking (< 5 pack-years, > 12 months)
- •Rheumatoid factor IgM and anti-CCP negative.
排除标准
- •RA and PsA patients
- •Severe cardiovascular disease, history or present (Myocardial infarction, Coronary bypass surgery
- •CVA, Pulmonary embolism and deep venous thrombosis, Heart failure)
- •A history of diabetes mellitus
- •Systemic inflammatory disease other than RA or PsA
- •Active pulmonary disease, including extraarticular manifestation of RA, asthma, COPD, TBC, infection
- •Cancer diagnosed and treated within 5 years, or known incomplete remission if earlier
- •Presence or recent history (4 weeks) of paradontitis
- •History of upper or lower respiratory infection in the past 4 weeks
- •The use of inhalation medication in the past 4 weeks
- •The patient has an active infection or used antibiotics in the last 7 days
- •The patient has started * 28 days for inclusion with oral or systemic corticosteroids in a dosage of > 10 mg a day or has had intramuscular and intraarticular corticosteroids
- •The patient has stopped treatment with etanercept < 1 month, or adalimumab, infliximab, tocilizumab or abatacept < 3 months, or rituximab > 12 months
- •Eating (including chewing gum), drinking, brushing teeth < 2 hours before measurements
- •The patient smokes
- •Lack of comprehension of the study and measurements
- •Unstable hyper- or hypothyroid function or change in the levothyroxine dosage * 28 days for inclusion
- •A history of renal insufficiency / liver insufficiency
- •The patient is not suited for participating in the study, according to the researcher;Controls
- •Severe cardiovascular disease, history or present (Myocardial infarction, Coronary bypass surgery, CVA, Pulmonary embolism and deep venous thrombosis, Heart failure)
- •A history of diabetes mellitus
- •Systemic inflammatory disease
- •Active pulmonary disease, including extraarticular manifestation of RA, asthma, COPD, TBC, infection.
- •Cancer diagnosed and treated within 5 years, or known incomplete remission if earlier
- •Presence or recent history (4 weeks) of paradontitis
- •History of upper or lower respiratory infection in the past 4 weeks
- •The use of inhalation medication in the past 4 weeks
- •The patient has an active infection or used antibiotics in the last 7 days
- •The patient has started * 28 days for inclusion with oral or systemic corticosteroids in a dosage of > 10 mg a day or has had intramuscular and intraarticular corticosteroids
- •Eating (including chewing gum), drinking, brushing teeth < 2 hours before measurements
- •Patient smokes
- •Lack of comprehension of the study and measurements
- •Unstable hyper- or hypothyroid function or change in the levothyroxine dosage * 28 days for inclusion
- •A history of renal insufficiency / liver insufficiency
- •History of/or active artritis
- •The patient is not suited for participating in the study, according to the researcher
研究者
相似试验
尚未招募
不适用
Diagnostic Accuracy of an Electronic Nose as Compared to Combined Conventional CT-Scanning, Autofluorescense Scopy for the Detection of Early Endobronchial Squamous Cell Cancer after prior History of Head-and-neck Cancer or Lung CancerEarly Endobronchial Squamous Cell Cancer1002747610029107NL-OMON36533Academisch Medisch Centrum315
已完成
不适用
The electronic nose as a diagnostic tool in the discrimination of COPD and controlsNL-OMON23287Academic Medical Center Amsterdam, The Netherlands120
已完成
不适用
An electronic nose in the screening for COPD in an at risk population of (ex-)smokers.COPD, smokingNL-OMON20180Academic Medical CenterUniversity of AmsterdamDept. Pulmonology, F5-260Meibergdreef 91105 AZ AmsterdamThe NetherlandsUniversity Medical Center UtrechtUniversity of UtrechtDept. PulmonologyHeidelberglaan 1003584 CX UtrechtThe NetherlandsThe Nelson Study Group (Nederlands-Leuvens Longkanker Screeningsonderzoek).250
招募中
不适用
Clinical study of a novel T-cell function assay for graft-versus-host disease (GVHD) after allogenic hematopoietic stem cell transplantatioJPRN-UMIN000046860The University of Tokyo50
已完成
不适用
Validation of a modified electronic nose for detection of oxidative stress in exhaled breathOXIDATIVERSTRESSDRKS00015258Klinik für Anaesthesiologie, Klinikum der Universität München - Campus Großhadern15